Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026
Talphera (Nasdaq: TLPH) will release Q1 2026 financial results after market close on Wednesday, May 13, 2026, followed by a live webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Talphera (Nasdaq: TLPH) will release Q1 2026 financial results after market close on Wednesday, May 13, 2026, followed by a live webcast and conference call at 4:30 p.m. ET / 1:30 p.m. PT.
The webcast includes a slide presentation; a replay will be available on the Talphera investor website for 90 days. Dial-in details and conference ID 24180 are provided for live participation.
Details
News Market Reaction – TLPH
On May 8, the first trading day after this news, TLPH closed 2.89% above the previous close.
Data tracked by StockTitan Argus for the May 8 session.
Key Figures
- Earnings call date
- May 13, 2026
- Q1 2026 results release after market close
- Call time (ET)
- 4:30 p.m. Eastern Time
- Start time for Q1 2026 webcast and conference call
- Call time (PT)
- 1:30 p.m. Pacific Time
- Corresponding West Coast time for the call
- Replay availability
- 90 days
- Webcast replay duration on Talphera’s investor website
- North America dial-in
- 1-800-836-8184
- Domestic access number for the conference call
- International dial-in
- 1-646-357-8785
- International access number (toll applies)
- Conference ID
- 24180
- Identifier for participants joining the earnings call
Previous Earnings Reports
-
Q4 and 2025 results, NEPHRO enrollment at 50%, financing and cash update.
-
Q3 results, private placement tranche, cash position and expense guidance cut.
-
Q2 results, reduced operating expenses, trial enrollment update and new financing.
-
Q1 results, FDA-approved patient reduction, improved loss and added financing.
-
Q4 and 2024 results, NEPHRO design change, cash and expense improvements.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Webcast Information
The webcast can be accessed here or by visiting the Investors section of the Company's website at www.talphera.com and clicking on the webcast link posted within Investors/News & Events/Upcoming Events section. The webcast will include a slide presentation and a replay will be available on the Talphera website for 90 days following the event.
Conference Call Information
Investors who wish to participate in the conference call may do so by dialing 1-800-836-8184 for North American callers, or 1-646-357-8785 (toll applies) for international callers outside of
About Talphera, Inc.
Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera's lead product candidate, Niyad® is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption (IDE) as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation status from the U.S. Food and Drug Administration (FDA).
This release is intended for investors only. For additional information about Talphera, please visit www.talphera.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/talphera-to-host-first-quarter-financial-results-and-corporate-update-call-and-webcast-on-wednesday-may-13-2026-302764770.html
SOURCE Talphera, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.